Cefuroxime axetil (oral): Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Cefuroxime axetil is a second generation oral cephalosporin antibiotic. It was discovered by Glaxo now GlaxoSmithKline and introduced in 1987 asZinnat.[1] It was approved by FDA on Dec 28, 1987.[2] It is available by GSK as Ceftin in US | Cefuroxime axetil is a second generation oral [[cephalosporin]] antibiotic. It was discovered by Glaxo now GlaxoSmithKline and introduced in 1987 asZinnat.[1] It was approved by FDA on Dec 28, 1987.[2] It is available by GSK as Ceftin in US | ||
It is an acetoxyethyl ester prodrug of cefuroxime which is effective orally.The activity depends on in vivo hydrolysis and release of cefuroxime. | It is an acetoxyethyl ester prodrug of cefuroxime which is effective orally.The activity depends on in vivo hydrolysis and release of cefuroxime. | ||
| Line 10: | Line 10: | ||
==Category== | ==Category== | ||
Cephalosporins, second generation. | [[Cephalosporins]], second generation. | ||
==US Brand Names== | ==US Brand Names== | ||
Revision as of 03:56, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Overview
Cefuroxime axetil is a second generation oral cephalosporin antibiotic. It was discovered by Glaxo now GlaxoSmithKline and introduced in 1987 asZinnat.[1] It was approved by FDA on Dec 28, 1987.[2] It is available by GSK as Ceftin in US
It is an acetoxyethyl ester prodrug of cefuroxime which is effective orally.The activity depends on in vivo hydrolysis and release of cefuroxime.
Category
Cephalosporins, second generation.
US Brand Names
CEFTIN®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | Compatibility and Stability | How Supplied | Labels and Packages
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050605s042lbl.pdf